Kamijo K, Saito A, Kato T, Kawasaki K, Suzuki M, Yabana T, Yachi A, Wada T
Endocrinol Jpn. 1982 Apr;29(2):177-81. doi: 10.1507/endocrj1954.29.177.
Nine healthy female controls and 10 hyperthyroid female patients were studied. The intravenous administration of 200 mg cimetidine, an H2-receptor antagonist, was followed by a significant and marked rise in serum prolactin levels in all control subjects. There was no significant difference in serum PRL response to cimetidine injection between the euthyroid controls and hyperthyroid patients. But max delta PRL, the change from basal to peak values, is significantly lower in the hyperthyroid patients than in the controls. There was a significant negative correlation between max delta PRL and serum T4 or T3 levels in hyperthyroid patients before and after treatment with MMI or PTU. It appears from our data that cimetidine induced PRL release was blunted in hyperthyroid patients.
对9名健康女性对照者和10名甲状腺功能亢进女性患者进行了研究。在所有对照者中,静脉注射200毫克H2受体拮抗剂西咪替丁后,血清催乳素水平显著且明显升高。甲状腺功能正常的对照者和甲状腺功能亢进患者之间,血清催乳素对西咪替丁注射的反应无显著差异。但是,甲状腺功能亢进患者从基础值到峰值的最大催乳素变化量(max delta PRL)明显低于对照者。在使用甲巯咪唑(MMI)或丙硫氧嘧啶(PTU)治疗前后,甲状腺功能亢进患者的max delta PRL与血清T4或T3水平之间存在显著负相关。从我们的数据来看,西咪替丁诱导的催乳素释放似乎在甲状腺功能亢进患者中受到了抑制。